Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
ATLANTA – Blood TMB predicts survival benefit in mNSCLC patients treated with first-line durvalumab plus tremelimumab versus chemo, according to...
News
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
News
ENCORE-601: Entinostat/pembrolizumab safe, active for melanoma
ATLANTA – Combined therapy with the HDAC inhibitor entinostat and the PD-1 inhibitor pembrolizumab has significant clinical activity and...
News
Novel CAR T, anti-PD-1 combo shows promise in MPD
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
Video
Dr. Louis Weiner: AACR presentations highlight new “transformative strategies”
ATLANTA – Studies featured during a press briefing at the AACR annual meeting, including work on a cancer preventive...
News
ACP: Average-risk women under 50 can postpone mammogram
Reducing breast cancer overdiagnosis and overtreatment was a goal of the ACP guideline’s authors.
Video
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
ATLANTA – Lynch syndrome is serving as a platform for the development of immunoprevention cancer vaccines.
Video
UNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZL
ATLANTA – The phosphoinositide 3-kinase delta inhibitor is active as a single-agent therapy in patients with relapsed or refractory marginal zone...
News
Tisotumab vedotin shows promise in recurrent, metastatic cervical cancer
The novel antibody-drug conjugate tisotumab vedotin (TV) shows encouraging activity and tolerability in heavily pretreated recurrent or metastatic...
News
Study explores third-line trabectedin plus PLD for BRCA1/2 ovarian cancer
Adding trabectedin to PLD significantly prolonged OS and PFS in BRCA1/2 patients with advanced epithelial OC, according to a prespecified phase 3...
News
Study: Racial disparities in gyn-onc trial enrollment persist
HONOLULU – A literature review shows that racial disparities in trial enrollment remain and may be increasing;...
News
ARIEL3 analysis: Rucaparib PFS benefit in recurrent OC occurs across age groups
HONOLULU – The improved PFS seen with maintenance rucaparib vs. placebo in women with recurrent ovarian cancer in...
News
Neratinib shows promise in HER2-mutant cervical cancer
HONOLULU – Treatment leads to durable responses and disease control in heavily pretreated metastatic patients with...
News
WISP: Early data provide further support for ISDO in women at high OC risk
HONOLULU – RRSO or ISDO each lead to significant reductions in cancer distress, but regret is greater with RRSO,...
News
Preliminary data show similar declines in worry, low regret with RRSO and RRS/RRO
HONOLULU – Early findings from the TUBA trial suggest similar declines in worry among women with BRCA1/2 mutations who undergo risk-reducing...